Mina, Roberto http://orcid.org/0000-0002-8144-541X
Joseph, Nisha S.
Gay, Francesca http://orcid.org/0000-0002-8619-412X
Kastritis, Efstathios http://orcid.org/0000-0001-8191-5832
Petrucci, Maria Teresa
Kaufman, Jonathan L. http://orcid.org/0000-0002-5687-6429
Montefusco, Vittorio
Gavriatopoulou, Maria
Patriarca, Francesca
Omedé, Paola
Boise, Lawrence H. http://orcid.org/0000-0001-9436-8815
Roussou, Maria
Giuliani, Nicola
Oliva, Stefania
Offidani, Massimo
Belotti, Angelo
Jaye, David L.
De Paoli, Lorenzo
Terpos, Evangelos http://orcid.org/0000-0001-5133-1422
Lonial, Sagar
Boccadoro, Mario
Nooka, Ajay K. http://orcid.org/0000-0003-4165-6869
Dimopoulos, Meletios A.
Article History
Received: 11 February 2020
Revised: 6 March 2020
Accepted: 26 March 2020
First Online: 14 April 2020
Conflict of interest
: R.M. has received honoraria from Amgen, Celgene, Takeda, and Janssen; has served on the advisory boards for Janssen. F.G. has received honoraria from Amgen, Celgene, Janssen, Takeda, and Bristol-Myers Squibb; has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, Roche, AbbVie, Adaptive, and Seattle Genetics. E.K. has received honoraria by Amgen, Genesis Pharma, Janssen, Takeda, and research grants from Amgen and Janssen. M.T.P. has received honoraria from and served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. J.L.K. has consulted for Roche, AbbVie, Janssen, BMS, Takeda, and Karyopharm. V.M. has received honoraria from Amgen, Celgene, Bristol-Myers-Squibb, and Janssen. F.P.: advisory role: Janssen, Celgene, MSD Italy; travel, accomodations, expenses: Celgene, Jazz, Medac. P.O. has served on the advisory board for Janssen. L.H.B. has received honoraria from AstraZeneca and undertaken consultancy for AbbVie and AstraZeneca. N.G. has received honoraria from Bristol-Myers Squibb, Celgene, Janssen; has served on the advisory boards for Amgen, Celgene, Takeda, Janssen; has received research funding from Celgene, Janssen; has received sponsorship for clinical trials from GlaxoSmithKline, Janssen, and Takeda. S.O. has received honoraria from Amgen, Celgene, and Janssen; has served on the advisory boards for Adaptive Biotechnologies, Janssen, Amgen, and Takeda. M.O. has received honoraria from Amgen, BMS, Celgene, Janssen, Takeda, and served on the advisory boards for Amgen, BMS, Celgene, Janssen, and Takeda. A.B. has served on the advisory boards for Amgen, Celgene, and Janssen. L.D.P. has received honoraria from and served on the advisory boards for Amgen, Janssen, Celgene, and Shire. E.T. has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb; has received research support from Amgen, Celgene, and Janssen. S.L. has consulted for Takeda, Celgene, Novartis, Janssen, GSK, Bristol-Myers Squibb, and Merck. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, AbbVie, and Bristol-Myers Squibb; has received research funding from Celgene, Janssen, Amgen, Bristol-Myers Squibb, Mundipharma, Novartis, and Sanofi. A.K.N. has served on the advisory board for GSK, Spectrum, Celgene, Amgen, Novartis Pharmaceuticals, Adaptive Biotechnologies; has received honoraria from Bristol-Myers Squibb and Janssen Pharmaceuticals. M.A.D. has received honoraria from participation in advisory boards for Amgen, Celgene, Janssen, Bristol-Myers Squibb, and Takeda. The remaining authors declare that they have no conflict of interest.